From Hypoxia to Bone: Reprogramming the Prostate Cancer Metastatic Cascade
International Journal of Molecular Sciences · 01.08.2025 · 26 (15) · 7452
DOI: 10.3390/ijms26157452 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.08.2025. Verfasst von Melissa Santos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Mechanisms and Biomarkers Research Group, School of Life Sciences, University of Westminster, London W1W 6UW, UK. Hauptthemen laut MEDLINE: Bone Neoplasms, Prostatic Neoplasms, Hypoxia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Westminster, Quintin Hogg Trust Research Studentship.
Abstract (Originalsprache)
Bone is the most frequent site of distant metastasis in advanced prostate cancer (PCa), contributing substantially to patient morbidity and mortality. Hypoxia, a defining feature of the solid tumour microenvironment, plays a pivotal role in driving bone-tropic progression by promoting epithelial-to-mesenchymal transition (EMT), cancer stemness, extracellular matrix (ECM) remodelling, and activation of key signalling pathways such as Wingless/Integrated (Wnt) Wnt/β-catenin and PI3K/Akt. Hypoxia also enhances the secretion of extracellular vesicles (EVs), enriched with pro-metastatic cargos, and upregulates bone-homing molecules including CXCR4, integrins, and PIM kinases, fostering pre-metastatic niche formation and skeletal colonisation. In this review, we analysed current evidence on how hypoxia orchestrates PCa dissemination to bone, focusing on the molecular crosstalk between HIF signalling, Wnt activation, EV-mediated communication, and cellular plasticity. We further explore therapeutic strategies targeting hypoxia-related pathways, such as HIF inhibitors, hypoxia-activated prodrugs, and Wnt antagonists, with an emphasis on overcoming therapy resistance in castration-resistant PCa (CRPC). By examining the mechanistic underpinnings of hypoxia-driven bone metastasis, we highlight promising translational avenues for improving patient outcomes in advanced PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Mechanisms and Biomarkers Research Group, School of Life Sciences, University of Westminster, London W1W 6UW, UK.
- UCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
ORCID-Profile: Melissa Santos, Dafydd Alwyn Dart, Pinar Uysal-Onganer
Förderung
- University of Westminster
- Quintin Hogg Trust Research Studentship
Zitieren
APA
Santos, M., Koushyar, S., Dart, D. A., & Uysal-Onganer, P. (2025). From Hypoxia to Bone: Reprogramming the Prostate Cancer Metastatic Cascade. International Journal of Molecular Sciences, 26(15), 7452. https://doi.org/10.3390/ijms26157452
Vancouver
Santos M, Koushyar S, Dart DA, Uysal-Onganer P. From Hypoxia to Bone: Reprogramming the Prostate Cancer Metastatic Cascade. International Journal of Molecular Sciences. 2025;26(15):7452. doi:10.3390/ijms26157452
BibTeX
@article{Santos2025,
author = {Santos, Melissa and Koushyar, Sarah and Dart, Dafydd Alwyn and Uysal-Onganer, Pinar},
title = {From Hypoxia to Bone: Reprogramming the Prostate Cancer Metastatic Cascade},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {15},
pages = {7452},
doi = {10.3390/ijms26157452}
}
EUVIMED